Penem prodrugs
AssigneePfizer Inc.
InventorsKatherine E. BRIGHTY, Anthony Marfat, Dale G. Mcleod, John P. O'Donnell
Life of this patent
Estimating the term…
Abstract
Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof preparation thereof formulation thereof and use to treat and prevent infection in mammals such as humans. This abstract is not limiting to the invention.
Claims10
A compound of the formula:
The compound of claim 15 which is 2-ethoxy-2-methyl-1-oxopropoxy)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate.
The compound of claim i, which is 2-ethoxy-2-methyl-1-oxopropoxy)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[[(1R,3S)-tetrahydro-1-oxido-3-thienyl]thio]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate in the crystalline form having an X-ray powder diffraction pattern substantially the same as that represented in FIGS. 4 and 6.
The method of claim 65 wherein said compound of claim 2 is administered in an amount of about 500 mg to about 2500 mg BID or TID to a human in need thereof.
Dependencies are inferred from the claim text.